

LivaNova

Health innovation that matters

Our Mission

At LivaNova, we unite to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart.

We address patients' and providers' critical needs by improving quality of life, safety and access while reducing complications, hospitalization and cost.

Our Strategy


To realize our full value, we focus on **Core Growth** to continue our leadership positions in underserved markets; **Pipeline Execution** to accelerate growth via clinical studies and delivering next-generation products; and **Operational Excellence** to drive margin expansion and increase return on investments.

Worldwide Footprint

Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs approximately 2,900 employees.

Proforma revenues by geography based on full-year 2022 net sales of \$1.02B:

US: 56% **EU: 17%** **ROW: 27%**



The Markets We Serve

Listed on Nasdaq stock exchange as **LIVN**

NEUROMODULATION	CARDIOPULMONARY	ADVANCED CIRCULATORY SUPPORT
Creator of VNS Therapy™	Market-leading positions	Focused on advanced temporary support solutions
* Sales \$477M	* Sales \$500M	* Sales \$39M
Disease States <ul style="list-style-type: none"> • Difficult-to-treat depression • Obstructive sleep apnea • Drug-resistant epilepsy 	Disease States <ul style="list-style-type: none"> • Coronary artery disease • Congenital heart defect • Atrial fibrillation • Valvular disease 	Disease States <ul style="list-style-type: none"> • Cardiogenic shock • Cardiac arrest • Left and right ventricle failure • ARDS/COPD/Acute Respiratory Failure
Customers <ul style="list-style-type: none"> • Neurologists • Epileptologists • Psychiatrists • Neurosurgeons • ENT Specialists 	Customers <ul style="list-style-type: none"> • Perfusionists • Intensivists • Cardiac Surgeons • Cardiologists • Interventional Cardiologists 	Customers <ul style="list-style-type: none"> • Perfusionists • Intensivists • Cardiac Surgeons • Cardiologists • Interventional Cardiologists

* Sales based on full-year 2022. Numbers may not add precisely due to rounding

Our Core Products

Click the products below to learn more

EPILEPSY*

SenTiva™

Enhanced programming features, customizable treatment and therapy management while patients live their lives

125,000+ patients treated with VNS Therapy worldwide



ADVANCED CIRCULATORY SUPPORT (ACS)*

LifeSPARC™

Life Support Simplified.
For more patients, in more places

\$1 billion opportunity
advancing the standard of care



CARDIOPULMONARY*

Essenz™

Perfusion System
designed to meet the modern needs of the New Era of Perfusion

Built on a 50-year
legacy of
safety and reliability



Inspire™ Oxygenator

personalized perfusion – safe,
easy and flexible
for all adult patient sizes

3 million+
patients treated
to date



XTRA™ ATS

lowers the transfusion rates
during and after cardiac
surgery^{1,2}

4 million+
patients treated
to date



Strategic Portfolio Initiatives*

LivaNova has a differentiated pipeline targeting medical conditions with high unmet needs:

- **Difficult-to-Treat Depression (DTD):** VNS Therapy shows a significant improvement in quality of life and provides long-term protection from depressive symptoms.
- **Obstructive Sleep Apnea (OSA):** The therapy consists of an innovative, CPAP alternative, fully implantable device called the aura6000™. Specifically designed to reduce or eliminate moderate to severe sleep apnea.

Improving quality of life for patients worldwide

LivaNova
Health innovation that matters



www.livanova.com

20 Eastbourne Terrace
London, W2 6LG, United Kingdom
+1 281-895-2382

*Products not approved in all geographies. Consult your labeling. Click appropriate links to access safety information: [VNS Therapy-Epilepsy \(US\)](#); [VNS Therapy-Epilepsy \(OUS\)](#); [LifeSPARC \(US\)](#); [Essenz Perfusion System](#); [Inspire Oxygenator](#); [XTRA ATS](#); [VNS Therapy-Depression \(US\)](#); [VNS Therapy-Depression \(OUS\)](#); and [OSA](#). For OSA – caution: limited by United States law to investigational use. 1.Vonk et al. Intraoperative cell salvage is associated with reduced postoperative blood loss and transfusion requirements in cardiac surgery: a cohort study. Transfusion. 2013 Nov;53(11):2782-9. | 2.Côté et al. Efficacy of intraoperative cell salvage in decreasing perioperative blood transfusion rates in first-time cardiac surgery patients: a retrospective study. Can J Surg 2016 Sep;59(5):330-6.